BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25871400)

  • 1. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
    Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
    Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
    Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
    Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
    Dieudonné FX; Marion A; Marie PJ; Modrowski D
    J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
    Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
    Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salinomycin exerts anti-colorectal cancer activity by targeting the β-catenin/T-cell factor complex.
    Wang Z; Zhou L; Xiong Y; Yu S; Li H; Fan J; Li F; Su Z; Song J; Sun Q; Liu SS; Xia Y; Zhao L; Li S; Guo F; Huang P; Carson DA; Lu D
    Br J Pharmacol; 2019 Sep; 176(17):3390-3406. PubMed ID: 31236922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
    Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
    Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
    Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
    Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
    J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salinomycin enhances doxorubicin sensitivity through reversing the epithelial-mesenchymal transition of cholangiocarcinoma cells by regulating ARK5.
    Yu Z; Cheng H; Zhu H; Cao M; Lu C; Bao S; Pan Y; Li Y
    Braz J Med Biol Res; 2017 Aug; 50(10):e6147. PubMed ID: 28832761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
    Wei W; Chua MS; Grepper S; So S
    Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
    Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
    Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
    Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.
    Feng H; Zhu M; Zhang R; Wang Q; Li W; Dong X; Chen Y; Lu Y; Liu K; Lin B; Guo J; Li M
    J Cell Mol Med; 2019 Apr; 23(4):2536-2548. PubMed ID: 30672133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
    Lim K; Han C; Dai Y; Shen M; Wu T
    Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.
    Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H
    Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma.
    Fan X; Ma X; Cui L; Dang S; Qu J; Zhang J; Wang X; Mao Z
    Oncotarget; 2016 Dec; 7(49):80404-80414. PubMed ID: 27829235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.